Over 1.4 billion adults globally live with hypertension (HTN) or high blood pressure, yet nearly half are unaware they have it, leaving many undiagnosed and untreated. This silent condition carries serious risks—unchecked HTN can lead to stroke and heart disease, both leading causes of early mortality.
While medications and lifestyle changes can help manage HTN, many people still fail to achieve target blood pressure, especially those with pregnancy, diabetes, or kidney disease. Despite new therapies and interventions, HTN-related complications and deaths continue to rise, particularly in low- and middle-income countries where aging populations are driving the increase.
Emerging research highlights the gut microbiome’s role in regulating blood pressure, suggesting that restoring intestinal function may offer a promising therapeutic approach. This new IPA blog will examine the underlying mechanisms and evidence supporting probiotics as a strategy to help manage HTN risk.
Hypertension, in brief
A diagnosis of HTN is made when blood pressure measures 140/90 mmHg or above, with the top number (systolic) reflecting pressure during heartbeats and the bottom (diastolic) indicating pressure between beats.
Risk Factors
Some risk factors for HTN cannot be controlled, including family history, age over 65 years, and existing conditions like diabetes or kidney disease. These non-modifiable factors increase an individual’s likelihood of developing high blood pressure.
Fortunately, many risk factors can be modified, including poor diet (high in salt, saturated and trans fats, and low in fruits and vegetables), physical inactivity, tobacco and alcohol use, and excess body weight. Environmental factors, particularly air pollution and chronic noise exposure, are also important contributors to HTN risk.
Management of hypertension
Typical medications used to treat HTN include diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. Unfortunately, these medications may have occasional side effects such as nausea, vomiting, constipation, erectile dysfunction, and fatigue.
Beyond lifestyle changes and medications, HTN may also be managed through device-based therapies, such as renal denervation or baroreceptor activation, as well as stress-reduction techniques like meditation, yoga, and biofeedback. These approaches highlight the growing interest in novel strategies to control blood pressure, including investigations into the gut microbiome.
The gut microbiota and hypertension
Emerging evidence highlights the gut as a central player in HTN.
Specific gut bacteria show a higher presence in individuals with HTN compared to those with normal blood pressure. Both humans and animal models with HTN exhibit reduced gut microbial richness and diversity, altered microbial composition, and lower levels of short-chain fatty acid (SCFA)-producing bacteria alongside higher levels of gram-negative bacteria, which release pro-inflammatory lipopolysaccharide (LPS). Through the gut-brain axis, these microbial changes can also influence blood pressure by affecting neural and immune signaling.
Many factors that raise blood pressure also change the makeup of gut microbes, creating another possible link to HTN. For example, a high-salt diet may reduce SCFA production, which may influence blood pressure, as seen in a rat model of HTN.
Gut microbial imbalance and shifts in metabolites play a major role in blood pressure regulation. Dysbiosis can weaken the gut barrier and trigger inflammation, activating systems that influence blood pressure, including renin-angiotensin-aldosterone, autonomic, and immune pathways.
In addition to microbiota changes, HTN can cause structural gut changes such as fibrosis, thicker muscle walls, and abnormal villi, which disrupt nutrient absorption, immune regulation, and microbial balance, all further contributing to elevated blood pressure, as seen in both clinical and animal studies.
Also, compelling evidence indicates a causal role for gut microbiota in blood pressure regulation, demonstrated by fecal transfer of HTN to germ-free mice.
This suggests that restoring intestinal integrity and microbial balance could help reduce blood pressure.
Gut microbiota modifications and effects on hypertension
While this section focuses primarily on probiotics, other interventions—such as prebiotics, fiber, and dietary patterns—also modulate the gut microbiota and may influence blood pressure. These topics can be explored in a future blog. For example, diets like the Mediterranean diet, high in polyphenols and omega-3s and low in sodium, encourage the growth of beneficial gut microbes that support cardiovascular health.
Probiotics can modify the gut microbiota through multiple mechanisms to help lower blood pressure:
Endothelial cell dysfunction improvement
Endothelial dysfunction and HTN form a harmful cycle, as impaired endothelial secretions worsen blood vessel function and elevate blood pressure. In obese mice fed a high-fat diet, Loigolactobacillus coryniformis improved endothelial function and reduced oxidative stress. In humans, Lactiplantibacillus plantarum supplementation enhanced vascular function and lowered systemic inflammation in men with coronary artery disease.
Reduction of vascular oxidative stress
Oxidative stress, driven by excess reactive oxygen species, reduces nitric oxide and causes blood vessel constriction, raising blood pressure. Certain probiotics, including Lactobacilli and Bifidobactera species, and their metabolites, have antioxidant effects that help control oxidative stress and protect blood vessels. In one rat study, Limosilactobacillus fermentum helped maintain gut balance and reduced vascular oxidative stress caused by long-term nitric oxide blockade.
Vascular inflammation reduction
Chronic inflammation contributes to endothelial dysfunction and worsens HTN. Gut microbes may drive this via pro-inflammatory pathways, including LPS from gram-negative bacteria, which is linked to HTN and vascular inflammation. Animal and clinical studies suggest that probiotics can reduce LPS-driven inflammation, improve vascular function, and help lower blood pressure.
Metabolite production
Gut dysbiosis alters metabolite production, disrupting signaling pathways that regulate blood pressure. Microbial metabolites such as SCFAs, vasoactive hormones, trimethylamine N-oxide (TMAO), LPS, and uremic toxins like indoxyl sulfate and p-cresyl sulfate influence vascular tone and inflammation.
SCFAs generally support blood pressure balance, whereas TMAO, LPS, and uremic toxins promote HTN. Microbially derived vasoactive hormones, such as serotonin and dopamine, can also influence vascular tone in either direction.
Short-chain fatty acids (SCFAs)
SCFAs—mainly acetate, propionate, and butyrate—are produced when gut microbes ferment fiber and can help lower blood pressure by influencing the gut–brain axis. They affect blood vessel relaxation, inflammation, and the nervous system control of the heart. In animal studies, propionate helps regulate cardiovascular function through sympathetic nerve activity, while acetate and butyrate stimulate the vagus nerve to send calming signals to the brain.
In hypertensive rats, supplementing with SCFA-producing probiotics—Limosilactobacillus fermentum and Bifidobacterium brevis—or adding fiber helped prevent increases in blood pressure. In humans, a three-week resistant starch intervention enriched with acetate and butyrate lowered 24-hour systolic blood pressure by about 6 mmHg.
Bioactive peptides
Certain gut microbes produce bioactive peptides that directly influence the renin–angiotensin–aldosterone system (RAAS), a central pathway in blood pressure regulation. Probiotics such as Lactobacillus helveticus and Bifidobacterium longum release ACE-inhibitory peptides during fermentation, which can reduce RAAS activity and lower blood pressure. These peptides act alongside SCFAs and other microbial effects—including antioxidant and anti-inflammatory actions—to modulate vascular tone and cardiovascular function, illustrating how multiple microbial pathways converge to influence HTN.
Vasoactive hormones
Several commensal gut microbes produce vasoactive hormones such as serotonin, dopamine, and norepinephrine, which help regulate blood vessel constriction and dilation, influencing blood pressure.
Trimethylamine N-oxide (TMAO)
TMAO, a gut-derived metabolite from red meat, eggs, and dairy, has been linked to higher blood pressure. One recent analysis found a causal relationship, suggesting that reducing TMAO production may help lower HTN. Several studies show that lowering TMAO levels—and taking multi-strain probiotics—can modestly reduce blood pressure, especially in hypertensive individuals.
Uremic toxins, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS)
Gut microbes produce uremic toxins such as indoxyl sulfate and p-cresyl sulfate from dietary protein and amino acid breakdown. When kidney function declines, these toxins build up, causing oxidative stress, arterial calcification, and disrupted vascular and hormonal balance—all contributing to higher blood pressure. Probiotics, prebiotics, and synbiotics may help reduce these toxin levels, as observed in a systematic review and meta-analysis.
More evidence
Together, these microbial effects—including modulation of metabolites, inflammation, endothelial function, gut barrier integrity, and RAAS activity—converge to influence vascular tone and blood pressure, highlighting the multiple pathways through which the gut microbiota regulates HTN.
Quite a few intervention studies in both animals and humans have supported the potential of probiotics to manage HTN by harnessing the diverse mechanisms discussed.
An umbrella meta-analysis, encompassing 14 meta-analyses and 15,494 participants, found that probiotic supplementation significantly lowered both systolic and diastolic blood pressure. The reduction in systolic pressure was particularly notable in older adults and in studies with longer intervention periods.
Takeaway
HTN affects over 1.4 billion adults worldwide, often going undiagnosed. Emerging research shows that the gut microbiota plays a key role in blood pressure regulation. Probiotics can help by producing SCFAs and bioactive peptides, reducing inflammation and oxidative stress, supporting endothelial and gut barrier function, and modulating RAAS and vasoactive metabolites. Both animal studies and human trials—including meta-analyses—demonstrate that probiotics can meaningfully lower blood pressure, highlighting gut-targeted strategies as a promising, multifaceted approach to managing HTN.
Image by Mohamed Hassan from Pixabay
Key references
Bartolomaeus, Hendrik et al. “Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage.” Circulation vol. 139,11 (2019): 1407-1421. doi:10.1161/CIRCULATIONAHA.118.036652
Bier, Ariel et al. “A High Salt Diet Modulates the Gut Microbiota and Short Chain Fatty Acids Production in a Salt-Sensitive Hypertension Rat Model.” Nutrients vol. 10,9 1154. 23 Aug. 2018, doi:10.3390/nu10091154
Bustos-Merlo, A et al. “Real-world efficacy and safety of baroreceptor activation therapy in a series of patients with refractory arterial hypertension.” Hipertension y riesgo vascular vol. 42,2 (2025): 67-71. doi:10.1016/j.hipert.2024.10.004
Centers for Disease Control and Prevention. “Leading Causes of Death“. CDC, 17 Sept. 2025.
Chen, Zouquan et al. “Probiotics: functional food ingredients with the potential to reduce hypertension.” Frontiers in cellular and infection microbiology vol. 13 1220877. 3 Jul. 2023, doi:10.3389/fcimb.2023.1220877
Dave, Lakshmi A et al. “Human gut endogenous proteins as a potential source of angiotensin-I-converting enzyme (ACE-I)-, renin inhibitory and antioxidant peptides.” Peptides vol. 76 (2016): 30-44. doi:10.1016/j.peptides.2015.11.003
Deng, Wenjun et al. “Beyond the Microbiome: The Gut’s Role in Hypertension.” Function (Oxford, England) vol. 6,5 (2025): zqaf037. doi:10.1093/function/zqaf037
Gatarek, Paulina, and Joanna Kaluzna-Czaplinska. “Trimethylamine N-oxide (TMAO) in human health.” EXCLI journal vol. 20 301-319. 11 Feb. 2021, doi:10.17179/excli2020-3239
Graboski, Amanda L, and Matthew R Redinbo. “Gut-Derived Protein-Bound Uremic Toxins.” Toxins vol. 12,9 590. 11 Sep. 2020, doi:10.3390/toxins12090590
Griffiths, M W, and A M Tellez. “Lactobacillus helveticus: the proteolytic system.” Frontiers in microbiology vol. 4 30. 5 Mar. 2013, doi:10.3389/fmicb.2013.00030
Grylls, Alina et al. “Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 137 (2021): 111334. doi:10.1016/j.biopha.2021.111334
Hahad, Omar et al. “The Cardiovascular Effects of Noise.” Deutsches Arzteblatt international vol. 116,14 (2019): 245-250. doi:10.3238/arztebl.2019.0245
Hashish, Rahma et al. “The Promising Role of Probiotics in the Prevention of Cardiovascular Risk Factors and Their Implication in Reducing Coronary Artery Disease: A Literature Review.” Cureus vol. 17,6 e86292. 18 Jun. 2025, doi:10.7759/cureus.86292
Jama, Hamdi A et al. “Prebiotic intervention with HAMSAB in untreated essential hypertensive patients assessed in a phase II randomized trial.” Nature cardiovascular research vol. 2,1 (2023): 35-43. doi:10.1038/s44161-022-00197-4
Khalesi, Saman et al. “Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials.” Hypertension (Dallas, Tex. : 1979) vol. 64,4 (2014): 897-903. doi:10.1161/HYPERTENSIONAHA.114.03469
Khalil, Hassan, and Roman Zeltser. “Antihypertensive Medications.” StatPearls [Internet], StatPearls Publishing, updated 8 May 2023, 2025-Jan-.
Li, Jing et al. “Gut microbiota dysbiosis contributes to the development of hypertension.” Microbiome vol. 5,1 14. 1 Feb. 2017, doi:10.1186/s40168-016-0222-x
Li, Jing et al. “The Role and Mechanism of Intestinal Flora in Blood Pressure Regulation and Hypertension Development.” Antioxidants & redox signaling vol. 34,10 (2021): 811-830. doi:10.1089/ars.2020.8104
Li, Lin et al. “Associations Between Gut Microbiota, Short-Chain Fatty Acids, and High-Salt Diet-Induced Hypertension in Rats.” Current medical science vol. 45,4 (2025): 715-724. doi:10.1007/s11596-025-00077-5
Lin, Wen-Yang et al. “Probiotics and their Metabolites Reduce Oxidative Stress in Middle-Aged Mice.” Current microbiology vol. 79,4 104. 14 Feb. 2022, doi:10.1007/s00284-022-02783-y
Mahdavi-Roshan, Marjan et al. “The Effects of Probiotics on Inflammation, Endothelial Dysfunction, and Atherosclerosis Progression: A Mechanistic Overview.” Heart, lung & circulation vol. 31,5 (2022): e45-e71. doi:10.1016/j.hlc.2021.09.006
Malik, Mobin et al. “Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease.” Circulation research vol. 123,9 (2018): 1091-1102. doi:10.1161/CIRCRESAHA.118.313565
Martinez-Quinones, Patricia et al. “Hypertension Induced Morphological and Physiological Changes in Cells of the Arterial Wall.” American journal of hypertension vol. 31,10 (2018): 1067-1078. doi:10.1093/ajh/hpy083
Młynarska, Ewelina et al. “Gut Microbiota and Gut-Brain Axis in Hypertension: Implications for Kidney and Cardiovascular Health-A Narrative Review.” Nutrients vol. 16,23 4079. 27 Nov. 2024, doi:10.3390/nu16234079
National Center for Complementary and Integrative Health. “Complementary Health Approaches for Hypertension.” NCCIH Clinical Digest, May 2021.
Nguyen, Thi Thuy Uyen et al. “Effects of Probiotics, Prebiotics, and Synbiotics on Uremic Toxins, Inflammation, and Oxidative Stress in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of clinical medicine vol. 10,19 4456. 28 Sep. 2021, doi:10.3390/jcm10194456
O’Donnell, Joanne A et al. “The gut microbiome and hypertension.” Nature reviews. Nephrology vol. 19,3 (2023): 153-167. doi:10.1038/s41581-022-00654-0
Ojangba, Theodora et al. “Comprehensive effects of lifestyle reform, adherence, and related factors on hypertension control: A review.” Journal of clinical hypertension (Greenwich, Conn.) vol. 25,6 (2023): 509-520. doi:10.1111/jch.14653
Opdebeeck, Britt et al. “Molecular and Cellular Mechanisms that Induce Arterial Calcification by Indoxyl Sulfate and P-Cresyl Sulfate.” Toxins vol. 12,1 58. 19 Jan. 2020, doi:10.3390/toxins12010058
Pluznick, Jennifer L. “Microbial Short-Chain Fatty Acids and Blood Pressure Regulation.” Current hypertension reports vol. 19,4 (2017): 25. doi:10.1007/s11906-017-0722-5
Poll, Brian G et al. “Gut Microbial Metabolites and Blood Pressure Regulation: Focus on SCFAs and TMAO.” Physiology (Bethesda, Md.) vol. 35,4 (2020): 275-284. doi:10.1152/physiol.00004.2020
Ramchandran, L, and N P Shah. “Proteolytic profiles and angiotensin-I converting enzyme and alpha-glucosidase inhibitory activities of selected lactic acid bacteria.” Journal of food science vol. 73,2 (2008): M75-81. doi:10.1111/j.1750-3841.2007.00643.x
Rashid, Sherzad K et al. “Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system.” PloS one vol. 9,5 e97458. 15 May. 2014, doi:10.1371/journal.pone.0097458
“Renal Denervation.” Penn Medicine, 2025.
Robles-Vera, Iñaki et al. “Microbiota and Hypertension: Role of the Sympathetic Nervous System and the Immune System.” American journal of hypertension vol. 33,10 (2020): 890-901. doi:10.1093/ajh/hpaa103
Robles-Vera, Iñaki et al. “Probiotics Prevent Dysbiosis and the Rise in Blood Pressure in Genetic Hypertension: Role of Short-Chain Fatty Acids.” Molecular nutrition & food research vol. 64,6 (2020): e1900616. doi:10.1002/mnfr.201900616
Robles-Vera, Iñaki et al. “The Probiotic Lactobacillus fermentum Prevents Dysbiosis and Vascular Oxidative Stress in Rats with Hypertension Induced by Chronic Nitric Oxide Blockade.” Molecular nutrition & food research vol. 62,19 (2018): e1800298. doi:10.1002/mnfr.201800298
Senoner, Thomas, and Wolfgang Dichtl. “Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target?.” Nutrients vol. 11,9 2090. 4 Sep. 2019, doi:10.3390/nu11092090
Soehnlein, Oliver, and Peter Libby. “Targeting inflammation in atherosclerosis – from experimental insights to the clinic.” Nature reviews. Drug discovery vol. 20,8 (2021): 589-610. doi:10.1038/s41573-021-00198-1
Stier, Charles T Jr. “Serotonin and dopamine in essential hypertension.” American journal of hypertension vol. 26,2 (2013): 151. doi:10.1093/ajh/hps085
Tokarek, Julita et al. “Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure.” International journal of molecular sciences vol. 24,2 1377. 10 Jan. 2023, doi:10.3390/ijms24021377
Tolu-Akinnawo, Oluwaremilekun et al. “Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review.” Cureus vol. 16,8 e66304. 6 Aug. 2024, doi:10.7759/cureus.66304
Toral, Marta et al. “The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice.” Clinical science (London, England : 1979) vol. 127,1 (2014): 33-45. doi:10.1042/CS20130339
Verhaar, Barbara J H et al. “Gut Microbiota in Hypertension and Atherosclerosis: A Review.” Nutrients vol. 12,10 2982. 29 Sep. 2020, doi:10.3390/nu12102982
Wang, Han et al. “Trimethylamine N-oxide and its precursors in relation to blood pressure: A mendelian randomization study.” Frontiers in cardiovascular medicine vol. 9 922441. 22 Jul. 2022, doi:10.3389/fcvm.2022.922441
Welathanthree, Malindi et al. “Cross-talk between microbiota-gut-brain axis and blood pressure regulation.” Clinical science (London, England : 1979) vol. 139,9 431–447. 8 May. 2025, doi:10.1042/CS20240787
World Health Organization. “Hypertension.” WHO, 25 Sept. 2025.
Yang, Tao et al. “Gut dysbiosis is linked to hypertension.” Hypertension (Dallas, Tex. : 1979) vol. 65,6 (2015): 1331-40. doi:10.1161/HYPERTENSIONAHA.115.05315
Yang, Tao, and Jasenka Zubcevic. “Gut-Brain Axis in Regulation of Blood Pressure.” Frontiers in physiology vol. 8 845. 25 Oct. 2017, doi:10.3389/fphys.2017.00845
Yang, Zhihua et al. “Gut microbiota and hypertension: association, mechanisms and treatment.” Clinical and experimental hypertension (New York, N.Y. : 1993) vol. 45,1 (2023): 2195135. doi:10.1080/10641963.2023.2195135
Yuan, Lin et al. “Effects of probiotics on hypertension.” Applied microbiology and biotechnology vol. 107,4 (2023): 1107-1117. doi:10.1007/s00253-023-12369-8
Zarezadeh, Meysam et al. “Effects of probiotics supplementation on blood pressure: An umbrella meta-analysis of randomized controlled trials.” Nutrition, metabolism, and cardiovascular diseases : NMCD vol. 33,2 (2023): 275-286. doi:10.1016/j.numecd.2022.09.005
Zhao, Yang et al. “Association of PM2.5 with hypertension, type 2 diabetes, and multimorbidity: evidence from the China Migrants Dynamic Survey of 165,075 individuals.” International journal of environmental health research, 1-14. 29 Sep. 2025, doi:10.1080/09603123.2025.2562028
Zhou, Donghao et al. “Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study.” Scientific reports vol. 8,1 9418. 20 Jun. 2018, doi:10.1038/s41598-018-27377-2
